Reporting of R&D Costs Under IAS 38 – The Case of Biopharmaceutical Companies
DOI :
https://doi.org/https://doi.org/10.37075/RP.2022.4.04Ключови думи :
Разходи за научноизследователска и развойна дейност, Нематериални активи, Биофармацевтична промишленост, Ваксини срещу COVID-19, Счетоводна политикаАбстракт
The objective of the paper is to provide insights into the effects of IAS 38 on the financial information provided by companies operating in the biopharmaceutical industry, taking into account the increased expenditure on research and development activities during the COVID-19 pandemic. Financial reports for 2019 and 2020 of BioNTech SE (the company responsible for the development of one of the authorized COVID-19 vaccines) are analysed and given as an example for how the capitalization and expensing of R&D costs affect the information provided by entities. Example for improvement of the R&D accounting treatment is presented in the case of IFRS 6 “Exploration for and Evaluation of Mineral Resources”.Литература (библиография)
Ocean Tomo LLC (2022). Intangible Asset Market Value Study - Ocean Tomo. DOI: https://oceantomo.com/INTANGIBLE-ASSET-MARKET-VALUE-STUDY/
{{OECD}} (2021). Main Science and Technology Indicators, Vol. 2021 Issue 1. Main Science and Technology Indicators. DOI: https://doi.org/10.1787/eea67efc-en
Andrea Shalal,David Lawder (2022). World Bank says will boost COVID-19 vaccine funding to $20 bln. DOI: https://www.reuters.com/business/healthcare-pharmaceuticals/world-bank-says-will-boost-financing-covid-19-vaccines-20-billion-2021-06-30/
Файлове за сваляне
Публикуван
Брой
Раздел (Секция)
Лиценз
Авторски права (c) 2022 Мария Маркова, Георги Христов (Автор)
Публикация с Creative Commons Attribution 4.0 International License.
Авторите запазват авторските права върху своите произведения.
Всички публикации се разпространяват при условията на лиценза Creative Commons Attribution 4.0 International (CC BY 4.0).
